Results 31 to 40 of about 8,627 (176)

Effectiveness of dabigatran etexilate for thromboprophylaxis of mechanical heart valves [PDF]

, 2011
ObjectiveWarfarin reduces risk of stroke in patients with mechanical heart valves but increases risk of hemorrhage and is difficult to use. Dabigatran etexilate, a new oral direct thrombin inhibitor, is safe and effective in reducing risk of stroke among
Rakesh M. Suri, Hartzell V. Schaff, Schaff, Hartzell V., Mark H. Ereth, Stephen H. McKellar, Stuart Abel, Ereth, Mark H., McKellar, Stephen H., Abel, Stuart, Camp, Christopher L., Suri, Rakesh M., Christopher L. Camp   +11 more
core   +1 more source

Monitoring the use of dabigatran etexilate for stroke prevention: compliance with renal function guidelines [PDF]

Journal of Primary Health Care, 2020
INTRODUCTIONDabigatran etexilate has become widely used in New Zealand, but information relating to when renal function monitoring is being undertaken is lacking.
Alesha J. Smith, Natalie J. Medlicott, David M. Reith, Bryan H. Simpson   +3 more
doaj  

Preclinical testing of dabigatran in trypsin-dependent pancreatitis

JCI Insight, 2022
Pancreatitis, the inflammatory disorder of the pancreas, has no specific therapy. Genetic, biochemical, and animal model studies revealed that trypsin plays a central role in the onset and progression of pancreatitis.
Zsófia Gabriella Pesei, Zsanett Jancsó, Alexandra Demcsák, Balázs Csaba Németh, Sandor Vajda, Miklós Sahin-Tóth   +5 more
doaj   +1 more source

Use of idarucizumab for emergency surgery in patients taking dabigatran

Атеротромбоз, 2022
This article presents modern possibilities for the provision of emergency surgical care to patients with atrial fibrillation, who administered dabigatran etexilate.
O. M. Nesterova, Y. R. Lentsik, A. A. Vitik, E. D. Kosmacheva, V. I. Fetisova, M. N. Zamyatin   +5 more
doaj   +1 more source

Dose tailoring of dabigatran etexilate: obvious or excessive? [PDF]

, 2015
Introduction: Dabigatran etexilate is used for preventing blood clots and tends to replace older anticoagulants in many of their indications. However, the ‘one dose fits all’ policy is subject to criticism.
Mullier, François, Douxfils, Jonathan, Douxfils, Jonathan; id_orcid, Dogné, Jean-Michel   +3 more
core   +1 more source

Pharmacogenetics of dabigatran etexilate interindividual variability [PDF]

, 2016
Introduction Dabigatran etexilate is given in fixed doses without coagulation monitoring for the prevention of blood clots in at risk adults. A high inter-individual variability in blood concentrations of the active metabolite of dabigatran has been ...
Vecchione, Gennaro, Dimatteo, Claudia, Buono, Matteo, Testa, Sophie, Grandone, Elvira, MARGAGLIONE, MAURIZIO, Cappucci, Filomena, Tiscia, Giovanni Luca, D'ANDREA, GIOVANNA, Paoletti, Oriana   +9 more
core   +1 more source

Normalization of Activated Partial Thromboplastin Time Correlates with Low Levels of Dabigatran in a Patient with Severe Sepsis

Case Reports in Critical Care, 2015
The oral anticoagulant dabigatran etexilate can be a challenge when patients need acute surgery. Sepsis and acute renal failure exacerbate the anticoagulant effect.
Rikke Ebenhard Højland, Stine Borch Thorup, Bodil Steen Rasmussen   +2 more
doaj   +1 more source

Dabigatran versus Warfarin for the Treatment of Pediatric Thromboembolism: A Pilot Randomized Trial [PDF]

Pharmaceutical Sciences, 2020
Background: Venous thromboembolism (VTE) is still a problematic situation in children. Drugs like warfarin, enoxaparin, and heparin are current standard of care in childhood VTE. This study was designed to compare the efficacy of warfarin with dabigatran
Aziz Eghbali, Roghayyeh Rahimi Afzal, Roya Sheikhbeygloo, Aygin Eghbali, Bahar Taherkhanchi, Bahador Bagheri   +5 more
doaj   +1 more source

Dabigatran etexilate dosing and monitoring in Aotearoa New Zealand [PDF]

, 2020
Introduction Dabigatran etexilate is a direct thrombin inhibitor that has become widely used in New Zealand. It has been available and fully subsidised in New Zealand since July 2011.
Simpson, Bryan Henry
core   +1 more source

Dabigatran Etexilate: A Review in Pediatric Venous Thromboembolism

, 2022
Declarations Funding The preparation of this review was not supported by any external funding. Authorship and Conflict of interest Julia Paik is a salaried employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest.
Julia Paik (6912664)
core   +1 more source